

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/178243 A1

- (51) **International Patent Classification:**
C12Q 1/6886 (2018.01) *G01N 33/574* (2006.01)
- (21) **International Application Number:**
PCT/US2022/016961
- (22) **International Filing Date:**
18 February 2022 (18.02.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|--------------------------------|----|
| 63/151,710 | 20 February 2021 (20.02.2021) | US |
| 63/196,620 | 03 June 2021 (03.06.2021) | US |
| 63/210,962 | 15 June 2021 (15.06.2021) | US |
| 63/215,838 | 28 June 2021 (28.06.2021) | US |
| 63/227,733 | 30 July 2021 (30.07.2021) | US |
| 63/250,634 | 30 September 2021 (30.09.2021) | US |
| 63/274,342 | 01 November 2021 (01.11.2021) | US |

(71) **Applicant:** KITE PHARMA, INC. [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) **Inventors:** BOT, Adrian; 3090 Franklin Canyon Drive, Beverly Hills, California 90210 (US). CHOU, Szu-Ting; c/

o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US). **PLAKS, Vicki**; 1138 12th Street, Apt. 8, Santa Monica, California 90403 (US). **PODDAR, Soumya**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US). **ROSSI, John**; 1427 Ramona Drive, Newbury Park, California 91320 (US).

(74) **Agent:** LOPEZ, Miguel A. et al.; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) **Title:** GENE MARKERS FOR SELECTING IMMUNOTHERAPIES

NOTABLE CHANGES
•INNATE IMMUNITY
MYELOID
MARKERS
ARG2
TREM2
IL8
C8G
MASP2




FIG. 1

(57) **Abstract:** The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade).

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*